SOUTH SAN FRANCISCO, Calif. — BreezeBio, formerly known as GenEdit, said it has closed a $60 million Series B financing to advance its internal pipeline of precision genetic medicines and expand its proprietary NanoGalaxy delivery platform.
The company said the financing will support the progression of its first therapeutic programs toward the clinic, including candidates targeting autoimmune disease and oncology, and reflects its transition from a delivery-focused platform company to a therapeutics developer.
“Now that we can deliver genetic payloads to the right cells with precision, we are building genetic medicines designed to make a real difference for patients,” said Kunwoo (Ryan) Lee, Ph.D., Chief Executive Officer of BreezeBio. “We’ve completed our transition from a delivery platform to a therapeutics company, and this financing allows us to advance our first internal programs toward the clinic while continuing to expand the reach of NanoGalaxy.”
BreezeBio’s lead therapeutic candidate, BRZ-101, is designed to restore immune tolerance in patients with type 1 diabetes. The therapy delivers mRNA-encoded autoantigens and tolerogenic co-factors to antigen-presenting cells, inducing antigen-specific regulatory T cells that suppress autoimmune responses without broadly impairing immune function. The company said preclinical studies demonstrated immune tolerance across multiple autoimmune disease models and showed favorable tolerability in animal studies. BRZ-101 is now advancing into IND-enabling studies.
The company’s NanoGalaxy platform underpins its therapeutic pipeline, enabling targeted delivery of genetic payloads to multiple organ systems, including immune, cardiac, pulmonary, and central nervous system tissues. BreezeBio said it is expanding the platform with ligand-based targeting to achieve additional tissue and cell specificity, including delivery to T cells to support in vivo CAR-based therapeutic approaches.
“BreezeBio is solving one of the most significant challenges in gene therapy, targeted delivery,” said Vincent Jeong, Managing Director at Yuanta Investment and lead investor in the Series B round. “With platform validation through strategic collaboration and clear progress toward clinical development, BreezeBio is approaching an important inflection point as it advances a differentiated internal pipeline designed to address significant unmet needs.”
Alongside its internal programs, BreezeBio said it continues to advance a multi-year collaboration and licensing agreement with Genentech, with research and development activities progressing following an initial milestone achievement last year.
The Series B financing was led by new investors Yuanta Investment and DSC Investment, with participation from several additional new and existing investors.
